Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 1 month later Oct 21, 2026 → Dec 15, 2027
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 87 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 21, 2026 to Dec 15, 2027
  2. Site details revised at 3 of 23 sites
  3. 4 versions Re-verified since Apr 8, 2026, no change to tracked fieldsv82-v85
  4. Primary and study completion dates: Oct 21, 2025 to Oct 21, 2026v81
  5. Re-verified, no change to tracked fieldsv80
Show 42 earlier versionsHide 42 earlier versions
  1. Study sites revised (23)v79
  2. Re-verified, no change to tracked fieldsv78
  3. Study sites revised (23)v77
  4. Primary and study completion dates: Oct 21, 2024 to Oct 21, 2025v76
  5. 2 versions Re-verified since Jul 2, 2024, no change to tracked fieldsv74-v75
  6. Study sites revised (23)v73
  7. Study sites revised (23)v72
  8. 2 versions Re-verified since Nov 7, 2023, no change to tracked fieldsv70-v71
  9. Primary and study completion dates: Oct 21, 2023 to Oct 21, 2024v69
  10. Start date: Jun 29, 2018 to Oct 12, 2018v68
  11. Re-verified, no change to tracked fieldsv67
  12. Study sites revised (23)v66
  13. 2 versions Re-verified since Mar 7, 2023, no change to tracked fieldsv64-v65
  14. Primary and study completion dates: Oct 21, 2022 to Oct 21, 2023v63
  15. 3 versions Re-verified since Jun 7, 2022, no change to tracked fieldsv60-v62
  16. Study sites revised (23)v59
  17. Re-verified, no change to tracked fieldsv58
  18. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 23 of 23 sites
    v57
  19. Site details revised at 1 of 23 sitesv56
  20. Site details revised at 1 of 23 sitesv55
  21. Site details revised at 2 of 23 sitesv54
  22. Site details revised at 4 of 23 sitesv53
  23. Study sites: 22 to 23v52
  24. Study sites: 21 to 22v51
  25. Site details revised at 1 of 21 sitesv50
  26. Site details revised at 1 of 21 sitesv49
  27. Primary and study completion dates: Oct 21, 2021 to Oct 21, 2022v48
  28. Study sites: 18 to 21v47
  29. Site details revised at 1 of 18 sitesv46
  30. Site details revised at 1 of 18 sitesv45
  31. Study sites: 17 to 18v44
  32. Site contacts updated at 1 of 17 sitesv43
  33. 2 versions Re-verified since Apr 13, 2021, no change to tracked fieldsv41-v42
  34. Phase: Phase 1/2 to Phase 2v40
  35. Re-verified, no change to tracked fieldsv39
  36. Site contacts updated at 1 of 17 sitesv38
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the side effects of bevacizumab and anetumab ravtansine or paclitaxel in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that does not respond to treatment (refractory). Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Anetumab ravtansine is a drug that targets a protein in the body called mesothelin, which can be found in some ovarian, pancreatic and other tumors. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving bevacizumab and anetumab ravtansine or paclitaxel may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
Trial Details
NCT Number NCT03587311
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov